Pakistan’s Citi Pharma Limited (CPHL) has officially begun exporting nutraceutical products to the United States, marking a significant milestone for the company. The announcement, made in a notice to the Pakistan Stock Exchange (PSX) on Friday, highlighted that these products, which received approval from the US Food and Drug Administration (FDA), launched in September 2024.
As Pakistan’s leading manufacturer of Active Pharmaceutical Ingredients (API), Citi Pharma expects to generate approximately $3 million annually from this new revenue stream, boasting profit margins between 25% to 30%. The FDA approval not only enhances Citi Pharma’s reputation but also strengthens its position as a global player, which may attract further investments and international collaborations. The company confirmed the receipt of $109,500 for its first shipment.
Nutraceuticals, which are dietary supplements offering health benefits beyond basic nutrition, have been approved for various categories, including fertility, weight management, stress and mood enhancement, skin and hair care, and joint and muscle relief.
Citi Pharma emphasized that the FDA approval reflects its commitment to meeting international quality standards, enabling the company to enter the competitive US market. Earlier, in July, Citi Pharma formed a strategic partnership with India’s Murli Krishna Pharma Private Ltd (MKPL) to supply APIs and products to the Pakistani market.
